MBRX - Moleculin Biotech, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7850
-0.0161 (-2.01%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.8011
Open0.8217
Bid0.0000 x 1300
Ask0.8900 x 1800
Day's Range0.7800 - 0.8217
52 Week Range0.3230 - 1.9700
Volume833,314
Avg. Volume2,128,206
Market Cap47.417M
Beta (5Y Monthly)2.40
PE Ratio (TTM)N/A
EPS (TTM)-0.2260
Earnings DateMar 19, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Is Moleculin Biotech (MBRX) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Moleculin Biotech (MBRX) Outperforming Other Medical Stocks This Year?

    Is (MBRX) Outperforming Other Medical Stocks This Year?

  • Moleculin Provides Update on Annamycin Clinical Development
    PR Newswire

    Moleculin Provides Update on Annamycin Clinical Development

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced an update on its clinical development plan for Annamycin.

  • Moleculin Biotech, Inc. (MBRX) Stock Sinks As Market Gains: What You Should Know
    Zacks

    Moleculin Biotech, Inc. (MBRX) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, Moleculin Biotech, Inc. (MBRX) closed at $0.96, marking a -0.38% move from the previous day.

  • New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model
    PR Newswire

    New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a peer-reviewed article published in Clinical Cancer Research (Clin Cancer Res June 30 2020 DOI:10.1158/1078-0432.CCR-19-4092) reported findings that Moleculin's STAT3 inhibitor, WP1066, used in combination with traditional whole brain radiation therapy (WBRT) resulted in long-term survivors and enhanced median survival time relative to monotherapy in mice with implanted human brain tumors.

  • ACCESSWIRE

    INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Moleculin Biotech, Inc. for Potential Breach of Fiduciary Duty Claims

    NEW YORK, NY / ACCESSWIRE / June 30, 2020 / Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Moleculin Biotech, Inc. (NASDAQ: MBRX ...

  • GlobeNewswire

    Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

    NEW YORK, June 29, 2020 -- Life Sciences Investor Forum today announced that the presentations from the June 25th conference are now available for on-demand viewing at.

  • Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases
    PR Newswire

    Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced a presentation at the American Association of Cancer Research (AACR) Annual Meeting held from June 22nd-24th, 2020, illustrating a unique approach to creating drugs capable of reaching tumors hiding in organs where existing anticancer drugs cannot accumulate in therapeutic concentrations. A poster presentation entitled, "Targeting Cancer Sanctuary Sites: A Novel Approach to the Treatment of Lung Localized Tumors," provided an overview of data demonstrating that uniquely high uptake and retention of Annamycin in the lungs results in consistently high in vivo activity against wide range of lung-localized tumors in mice.

  • GlobeNewswire

    Virtual Conference for Life Sciences Companies Broadcast Live June 25, 2020

    NEW YORK, June 23, 2020 -- Life Sciences Investor Forum today announced the agenda for its second quarterly event for public and private companies, investors and industry.

  • Moleculin to Present at the Life Sciences Investor Forum
    PR Newswire

    Moleculin to Present at the Life Sciences Investor Forum

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp, Chairman and Chief Executive Officer, will present at the Life Sciences Investor Forum being held virtually on June 25th, 2020 at 1:30pm ET.

  • Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?
    Zacks

    Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?

    Is (MBRX) Outperforming Other Medical Stocks This Year?

  • Moleculin Announces Confirmatory In Vitro Analysis of WP1122
    PR Newswire

    Moleculin Announces Confirmatory In Vitro Analysis of WP1122

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that a repeat of previous in vitro testing has corroborated the antiviral potential of WP1122.

  • Moleculin Announces Submission to Expand Clinical Sites in European AML Trial
    PR Newswire

    Moleculin Announces Submission to Expand Clinical Sites in European AML Trial

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it has submitted requests to Polish regulatory authorities for approval to open two additional clinical sites for its Phase 1/2 clinical study of Annamycin for the treatment of acute myeloid leukemia ("AML").

  • Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment
    PR Newswire

    Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that recruiting has begun and the first patient has been enrolled in the Emory University Phase 1 clinical trial of WP1066 for the treatment of brain tumors in children. The study is being conducted at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta.

  • Moleculin Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020
    PR Newswire

    Moleculin Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has received notification from Nasdaq that trading in the Company's common stock will resume on Thursday, May 28, 2020.

  • GlobeNewswire

    Nasdaq Scheduled Resumption in Moleculin Biotech, Inc.

    NEW YORK, May 27, 2020 -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading in Moleculin Biotech, Inc. (Nasdaq: MBRX) is scheduled to resume on Thursday, May 28,.

  • Moleculin Provides Update on Coronavirus Drug Development
    PR Newswire

    Moleculin Provides Update on Coronavirus Drug Development

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration ("FDA") has granted the Company's request for a Pre-IND Meeting to provide guidance regarding the Company's plan to study its drug candidate, WP1122, in a clinical trial for patients with COVID-19 (the disease caused by the SARS-CoV-2 coronavirus). In addition, Moleculin provided a general update on its WP1122 development efforts.

  • Moderna COVID-19 vaccine data is ‘baby-step’ in right direction: Expert
    Yahoo Finance Video

    Moderna COVID-19 vaccine data is ‘baby-step’ in right direction: Expert

    Professor of Medicine at Yale and Director of The Yale New Haven Hospital Center for Outcomes Research and Evaluation Dr. Harlan Krumholz joins Yahoo Finance’s Seana Smith to discuss Moderna’s recent headway in an early-stage coronavirus vaccine trial.

  • GlobeNewswire

    Nasdaq Halts Moleculin Biotech Inc.

    NEW YORK, May 18, 2020 -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that the trading halt status in Moleculin Biotech Inc. (Nasdaq: MBRX) was changed to "additional.

  • MarketWatch

    UPDATE: Moleculin Biotech, CNS Pharma shares remain halted on Nasdaq

    Moleculin Biotech Inc. and CNS Pharmaceuticals Inc. said Monday their shares remain halted on Nasdaq with the exchange seeking additional information from each company. Shares werehalted temporarily on May 1 by the Securities and Exchange Commission in a halt that was meant to expire at 11.59 p.m. on May 15. The halt came because of questions regarding the accuracy of information in the marketplace about a drug candidate for the coronavirus illness COVID-19, the SEC said. Moleculin's stock was halted along with CNS and WPD Pharmaceuticals Inc. , because of questions relating to a drug candidate called WP1122. CNS was working with WPD to develop the drug; WPD had previously licensed rights to a portfolio of drug candidates including WP1122 from Moleculin Biotech for certain regions.

  • Moleculin Announces Nasdaq Trading Halt Pending Receipt of Additional Information
    PR Newswire

    Moleculin Announces Nasdaq Trading Halt Pending Receipt of Additional Information

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that pending the receipt of additional information from the Company, Nasdaq has halted the trading in the Company's common stock. The Company is actively working with the staff of Nasdaq to provide it with all requested information, and hopes to begin trading as soon as possible.

  • MarketWatch

    UPDATE: Moleculin Biotech and CNS Pharma comment on SEC trading halt

    Moleculin Biotech Inc. and CNS Pharmaceuticals Inc. said Monday they did not solicit or have any advance knowledge about claims made by third parties about drug candidate WP1122 and its effect on COVID-19. The two Houston-based companies had their stocks temporarily halted by the Securities and Exchange Commission on May 1 over claims and information in the marketplace about WP1122, along with the stock of WPD Pharmaceuticals Inc. of Vancouver, British Columbia. WPD had previously licensed rights to a portfolio of drug candidates including WP1122 from Moleculin Biotech for certain regions, while CNS is working with WPD on development. In separate statements, the companies said those parties made claims and distributed information about WP1122 during the period stretching from March 20 and May 5 regarding the potential efficacy of the drug in dealing with the coronavirus that causes COVID-19. "The company neither solicited, had advance knowledge of, nor played any role in the preparation of such information, claims or statements," Moleculin said in a statement. "Moleculin encourages all investors and persons of interest to look at the Company's releases and filings regarding the potential development of WP1122 for the treatment of COVID-19." CNS used the same language in its release. The SEC halt is scheduled to end on May 15.

  • Moleculin Provides Additional Comments Regarding Trading Halt
    PR Newswire

    Moleculin Provides Additional Comments Regarding Trading Halt

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that since the May 1st, 2020 temporary suspension by the Securities and Exchange Commission (SEC) of trading in the securities of Moleculin Biotech, Inc. (MBRX), additional information has come to the Company's attention regarding claims disseminated by third parties.

  • Investor Alert: Kaplan Fox Investigates Moleculin Biotech, Inc.
    PR Newswire

    Investor Alert: Kaplan Fox Investigates Moleculin Biotech, Inc.

    Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Moleculin Biotech, Inc. ("Moleculin" or the "Company") (NASDAQ: MBRX). Investors who purchased Moleculin securities may be affected.

  • Moleculin Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 15, 2020
    PR Newswire

    Moleculin Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 15, 2020

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its intention to adjourn its 2020 Annual Meeting of Stockholders.

  • SEC Puts the Kibosh on 3 Biotech Stocks Hawking a Miracle Anti-Coronavirus Drug
    TipRanks

    SEC Puts the Kibosh on 3 Biotech Stocks Hawking a Miracle Anti-Coronavirus Drug

    Since early February, the U.S. Securities and Exchange Commission has issued a series of warnings to investors to beware of companies hawking miracle cures to the disease known as COVID-19. Surely everyone -- the SEC included -- is certainly eager to see a cure to the disease, which has claimed more than 257,000 lives, found.Still, there's an old adage that warns us that "if something sounds too good to be true, it probably is."So far, the SEC has felt compelled to halt trading in the shares of no fewer than 29 separate publicly-traded companies that are suspected of having made false or misleading statements about the efficacy of cures they're supposedly working on.The latest entries onto this ignominious list: CNS Pharmaceuticals (CNSP), Moleculin Biotech (MBRX), and WPD Pharmaceuticals (WCOTF) -- three unprofitable, revenue-less, sub-$100 million market capitalization microcaps trading for penny-stock (below $5) prices.As reported Tuesday, the SEC halted trading in the shares of all three companies Monday, saying it has "questions regarding the accuracy and adequacy of information in the marketplace about the company and its securities." Specifically, all three companies are apparently involved in working up a drug candidate labeled WP1122, which is being touted as a cure to COVID-19.In an April 13 CNS press release, CNS describes WP1122 as a "prodrug" that, once ingested and metabolized by a patient, will produce in vivo something called 2-deoxy-D-glucose, or "2-DG." Supposedly, 2-DG has been shown in independent research conducted at the University of Frankfurt, Germany (and have you ever noticed how miracle drugs always seem to be verified effective somewhere too far away to conveniently check?) to "reduce replication of the coronavirus by 100% in in vitro testing," reports Marketwatch. (By the way, the "research" has not been peer-reviewed).In a statement, CNS CEO John Climaco stood by "the accuracy and adequacy of information the company has released into the marketplace regarding the company and its product candidates."Be that as it may, perhaps you are wondering how three separate companies came to be involved in developing one and the same, hitherto unheard of coronavirus cure -- even one as miraculous as WP1122 -- in the first place? Well, the story goes like this:Once upon a time, Moleculin Biotech developed a portfolio of drug candidates that might (or might not) be good for something or other. At some point, WPD licensed the rights to develop these drugs, and at some other point, CNS wandered into the picture and signed an agreement to help WPD with that development, promising to pay WPD about $1 million to move WP1122 through a successful Phase 2 study, in return for WPD's promise to share in 50% of any eventual net sales of the drug once it passes that Phase, passes Phase 3 as well, and is eventually approved for sale on the market.Thus was this tangled web weaved.Now, thanks to the SEC, it appears that the jig is up. It only remains to be seen whether shareholders in the three companies will cry "foul" -- or thank the regulators for protecting investors from misinformation, and the pie-in-the-sky promises of penny stocks.In reaction, Maxim analyst Jason McCarthy noted, "Effective immediately, Maxim Group is temporarily suspending coverage of Moleculin Biotech, Inc. (MBRX) and removing the rating and price target due to the Order of Suspension of Trading of MBRX shares issued by the Securities and Exchange Commission (SEC) on May 1, 2020."To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.